Rigel Pharmaceuticals
RIGL
122 hedge funds and large institutions have $203M invested in Rigel Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 43 increasing their positions, 19 reducing their positions, and 11 closing their positions.
3,662% more call options, than puts
Call options by funds: $1.28M | Put options by funds: $34K
264% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 11
126% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 19
31% more funds holding
Funds holding: 93 → 122 (+29)
5% more capital invested
Capital invested by funds: $193M → $203M (+$10.4M)
0.94% more ownership
Funds ownership: 67.65% → 68.59% (+0.94%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$3.76M |
| 2 |
BlackRock
New York
|
+$3.58M |
| 3 |
Renaissance Technologies
New York
|
+$3.03M |
| 4 |
JP Morgan Chase
New York
|
+$2.96M |
| 5 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
+$2.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$17M |
| 2 |
AC
Armistice Capital
New York
|
-$7.36M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$5M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
-$2.54M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.77M |
RIGL Hedge Fund Activity: Q4 2024 in Review
122 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2024, worth a combined $203M — up 5.4% from $193M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new RIGL positions and 11 closed out — a net gain of 29 holders — while 43 added to existing stakes and 19 trimmed.
The largest buyer was Soleus Capital Management, adding an estimated $3.76M. The largest seller was Invesco, exiting entirely with an estimated $17M sold.
- 122 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2024, up from 93 in Q3 2024.
- Funds reported $203M of Rigel Pharmaceuticals stock for Q4 2024, up 5.4% quarter-over-quarter.
- 40 funds opened new Rigel Pharmaceuticals positions in Q4 2024 and 11 closed out, a net change of +29 holders.
- The largest Rigel Pharmaceuticals buyer in Q4 2024 was Soleus Capital Management, an estimated $3.76M added.
- The largest Rigel Pharmaceuticals seller in Q4 2024 was Invesco, an estimated $17M sold.
Based on aggregated 13F filings for Q4 2024.